TRCT
XTNT icon

Tower Research Capital (TRC)’s Xtant Medical Holdings XTNT Stock Holding History

Tower Research Capital (TRC)’s Portfolio XTNT Stock Details XTNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38K Buy
10,398
+3,010
+41% +$1.45K ﹤0.01% 4394
2026
Q1 		$4.12K Buy
7,388
+2,772
+60% +$1.71K ﹤0.01% 4228
2025
Q4 		$3.62K Buy
4,616
+1,046
+29% +$760 ﹤0.01% 4339
2025
Q3 		$2.32K Sell
3,570
-2,213
-38% -$1.4K ﹤0.01% 4650
2025
Q2 		$4.27K Sell
5,783
-86
-1% -$49 ﹤0.01% 4350
2025
Q1 		$2.76K Sell
5,869
-10,206
-63% -$5.37K ﹤0.01% 4511
2024
Q4 		$7.12K Buy
16,075
+10,758
+202% +$5.21K ﹤0.01% 4103
2024
Q3 		$3.59K Sell
5,317
-9,470
-64% -$6.26K ﹤0.01% 4812
2024
Q2 		$9.32K Buy
14,787
+12,525
+554% +$9.99K ﹤0.01% 4262
2024
Q1 		$2.65K Sell
2,262
-8,086
-78% -$8.87K ﹤0.01% 5003
2023
Q4 		$11.7K Sell
10,348
-3,745
-27% -$4.4K ﹤0.01% 4110
2023
Q3 		$15.5K Buy
14,093
+7,080
+101% +$7.6K ﹤0.01% 3612
2023
Q2 		$6.52K Buy
7,013
+1,734
+33% +$1.16K ﹤0.01% 4690
2023
Q1 		$3K Buy
+5,279
New +$3.85K ﹤0.01% 5256
2022
Q4 		– Sell
-11,914
Closed -$9K – 6458
2022
Q3 		$9K Buy
11,914
+988
+9% +$541 ﹤0.01% 4707
2022
Q2 		$6K Buy
10,926
+3,810
+54% +$2.26K ﹤0.01% 4964
2022
Q1 		$5K Sell
7,116
-3,153
-31% -$2.06K ﹤0.01% 5121
2021
Q4 		$6K Sell
10,269
-21,393
-68% -$20.2K ﹤0.01% 5075
2021
Q3 		$35K Buy
31,662
+23,432
+285% +$30.5K ﹤0.01% 3249
2021
Q2 		$13K Sell
8,230
-44,410
-84% -$79K ﹤0.01% 4247
2021
Q1 		$124K Buy
52,640
+31,033
+144% +$66.3K ﹤0.01% 2422
2020
Q4 		$26K Buy
21,607
+8,401
+64% +$10.8K ﹤0.01% 3703
2020
Q3 		$11K Buy
+13,206
New +$12.9K ﹤0.01% 4074
2016
Q3 		– Sell
-39
Closed -$1K – 4557
2016
Q2 		$1K Buy
39
+8
+26% +$206 ﹤0.01% 4230
2016
Q1 		$1K Buy
+31
New +$990 ﹤0.01% 3812
2015
Q4 		– Hold
0
– – – 5126
2015
Q2 		– Sell
-50
Closed -$2K – 5121
2015
Q1 		$2K Buy
+50
New +$2.01K ﹤0.01% 3844
2014
Q4 		– Sell
-27
Closed -$1K – 4772
2014
Q3 		$1K Buy
+27
New +$1.79K ﹤0.01% 4171

Other funds holding XTNT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Tower Research Capital (TRC)'s XTNT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Xtant Medical Holdings (XTNT) stake by 41% in Q2 2026, buying an estimated $1.45K and bringing the position to 10,398 shares worth $4.38K. The position accounts for ﹤0.01% of the portfolio, ranked #4394.

Tower Research Capital (TRC) first reported a position in XTNT in Q3 2014 and has held it in 27 quarters since. The position peaked at $124K in Q1 2021. 32 funds tracked by Wall St. Rank hold XTNT as of Q2 2026.

  • Tower Research Capital (TRC) held 10,398 shares of Xtant Medical Holdings worth $4.38K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,010 Xtant Medical Holdings shares in Q2 2026, an estimated $1.45K.
  • Xtant Medical Holdings made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4394 holding.
  • Tower Research Capital (TRC) first reported a position in Xtant Medical Holdings in Q3 2014 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Xtant Medical Holdings position peaked at $124K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.